you know who? THE consortium
It would be deserving(although long overdue) for all the novice investors that read your posts and are influenced by it.
Let's just put your record out there on the favorite stock you cover. These are your opinions on big valuation-changing events.
1) Lovenox - Nobody will get approval. WRONG
2) Lovenox - MNTA vs Amphastar - guaranteed settlement even before judge's PI order . WRONG
3) Copaxone - MNTA/NVS vs Teva High probability (77%?) that MNTA will win patent case. WRONG
Enough said. My last post.
I agree with all your points.
Long live the MNTA-README-FIRST boondoggling and argumentative clowns aka cult.
Completely agree. Cult provides invaluable service to the investor community and humanity in general. Their MNTA recommendations in 2007,2008,2009,2010,2011,2012 have been valuable.
forget to mention the other characteristics
1. incessant arguing about nothing in pretty much every single post...be it even something immaterial to the investment.
2. every message indicates he knows something better than the poster he is replying to
3. never seen him render any apology or admitting ever that he was wrong in his predictions ...despite the dubious record that i have pointed. boy EGO is something, isn't it?
You need some help as your conspiracy delusion keeps surfacing. It would also be better if you took responsibility for your own investment failures rather than trying to heap blame onto someone else.
Predicting the outcome of complex law suits is always a dice roll.
I will never forget a case I tried. After a three day trial to a jury, I thought we had won. The defense attorney complained that the case had not gone in as he wanted - he figured they lost. We could have settled favorably while the jury was out. But we lost big.
The court of appeals reversed and we ultimately did win but not the way we wanted.
MNTA lost on the patent in a district trial court that has no special expertise in patent law. The appeal will go to the the Federal Circuit which hears all patent case appeals. This case was never about whether MNTA infringed - it did. It was always about whether the TEVA patent was valid. We will not know that until the Federal Circuit rules.
In the mean time we may get a chance to buy MNTA sub-10.
I agree with what you are saying but looking at this as an investor regardless of what happens on appeal this is a huge victory for teva simply because of the time it will take to get a ruling on the appeal. It seems common from my past recollections that appeals could take years. There is really nothing that can be done in the interim to stop teva from enforcing its patent. It's not like manta can ask the appellate court to stay the district courts ruling and then begin producing the generic.
It would be in the best interest of the public to shut down the IHub boards. They have been used for years now by scammers such as Dew. Case in point is his "projection" of MNTA's valuation post mEnox approval in the sole generic scenario (which MNTA enjoyed for well over a year), which he put at $98/share.
He claims to save people from biotech scams and then makes outrageous and knowingly false statements like these. There are many examples on IHub of people who bought into his bull and have been burned badly. So what is it he is saving people from, exactly? Who will save them from him?
<It would be in the best interest of the public to shut down the IHub boards.>
The Ihub Biotech values board is the finest message board I have come across and it is also an excellent resource. There are a lot of intelligent people with scientific backgrounds there and they discuss biotech stocks and science in great detail.
<They have been used for years now by scammers such as Dew. Case in point is his "projection" of MNTA's valuation post mEnox approval in the sole generic scenario (which MNTA enjoyed for well over a year), which he put at $98/share.>
If you don't like it then don't go there. I don't recall reading Dew making a $98 share price prediction. Could you please provide a link to back up your claim?
What about M-118? The consortium was pretty high on its value at one time.
I wouldn't be surprised if the next negative news event will be a response from the FDA asking for clinical trials for mCopaxone before it can be approved.